Target intelligence / Profile preview

Chromosome 8 open reading frame 76 (C8orf76)

Target: C8orf76
Molecular classification: Other (Protein of uncharacterized/unknown family), Putative transcription factor

Overview

Chromosome 8 open reading frame 76 (C8orf76) is a protein-coding, nuclear-localized gene that is preferentially expressed and amplified in a range of human cancers, including gastric and liver cancer[2][4][5]. It likely functions as a transcriptional regulator, with evidence indicating it contains zinc-finger DNA-binding domains and interacts with promoters of genes such as lncRNA DUSP5P1 (activating the MAPK/ERK signaling axis in gastric cancer) and SLC7A11 (involved in ferroptosis in liver cancer)[2][4]. C8orf76 expression promotes cell proliferation, cell-cycle progression, suppression of apoptosis, and metastatic capabilities in multiple tumor models. Its amplification or overexpression is associated with poor prognosis and serves as a potential biomarker for cancer progression. Despite its critical role in oncogenesis, C8orf76 is not currently a direct therapeutic target, and no drugs are known to interact with it[2][3][4][5][6].

Other names: Chromosome 8 open reading frame 76C8orf76Uncharacterized protein C8orf76FLJ14825

Mechanism of action

Not applicable, as there are no known drugs or therapies that directly target C8orf76.

Biological functions

Transcription regulation (binds DNA at promoters, especially of lncRNA and protein-coding genes, and regulates gene expression—e.g., DUSP5P1, SLC7A11)Cell cycle regulation (promotes G1/S phase progression, upregulates cyclin D1/D3 and CDK4, inhibits inhibitors like p18, p53)Cell proliferation and tumorigenesis (promotes proliferation, migration, invasion; suppresses apoptosis, enhances tumor growth/metastasis in gastric and other cancers)Regulation of ferroptosis (positively regulates SLC7A11 transcription involved in ferroptosis in liver cancer)Potential: immune modulation and mRNA modification (based on pan-cancer multi-omics analysis)

Disease associations

Cancer (notably gastric, liver, breast, and other cancers where it is often amplified or overexpressed)Other (possible tumor suppressor role in select cancers where downregulated, but this remains to be clarified)

Safety considerations

Not established, as direct targeting has not been reported; theoretical concerns could include essential regulatory roles in proliferation and apoptosis that might impact normal tissues

Interacting drugs

None reported in current literature or databases; C8orf76 is not an established pharmacological target

Biomarkers

C8orf76 DNA copy-number amplification and mRNA/protein overexpression serve as prognostic biomarkers in gastric, breast, and possibly other cancers, being associated with poor outcomes or more aggressive disease

Beyond the preview

Go deeper on Chromosome 8 open reading frame 76 (C8orf76).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromosome 8 open reading frame 76 (C8orf76).

Explore the full profile